|
시장보고서
상품코드
2102314
더발루맙 시장 규모, 점유율, 성장 분석 : 적응증별, 치료법별, 유통 채널별, 최종사용자별, 제품 유형별, 투여 경로별, 지역별 - 업계 예측(2026-2033년)Durvalumab Market Size, Share, and Growth Analysis, By Indication, By Therapy Type, By Distribution Channel, By End User, By Product Type, By Route of Administration, By Region - Industry Forecast 2026-2033 |
||||||
세계의 더발루맙 시장 규모는 2024년에 15억 달러로 평가되었으며, 2025년 16억 4,000만 달러에서 2033년까지 32억 9,000만 달러로 확대되어 예측 기간(2026-2033년) 동안 CAGR 9.1%로 성장할 것으로 전망됩니다.
PD-L1을 표적으로 하는 인간 IgG1 단일클론 항체인 더발루맙은 면역종양학 시장에 큰 영향을 미치고 있습니다. 절제 불가능한 3기 비소세포폐암(NSCLC)에 대한 최초 승인에 이어, 이후 소세포폐암 및 요로상피암으로 적응증이 확대되면서 표준 치료에 비해 우수한 생존율이 입증됨에 따라 의료진의 채택이 확대되고 있습니다. 아스트라제네카와 제넨텍의 제휴를 통해 지역을 불문하고 시장 접근성이 확대되었으며, 제약사, 보험사, 암 치료 센터가 참여하는 견고한 생태계가 구축되었습니다. 주요 성장 요인으로는 체크포인트 억제 기전을 활용한 적응증 포트폴리오 확대와 더불어, 각종 암을 대상으로 진행 중인 임상시험을 들 수 있습니다. 또한, AI를 활용한 바이오마커 발견을 통해 맞춤형 치료 요법이 발전하고 있으며, 환자 선정의 최적화와 임상 현장에서의 도입 가속화가 이루어지고 있습니다. 이를 통해 더발루맙의 시장 지위가 강화되고 투자가 촉진되고 있습니다.
세계 더발루맙 시장의 성장요인
세계 더발루맙 시장의 주요 성장 촉진요인은 각종 암, 특히 비소세포폐암(NSCLC) 및 기타 고형암의 유병률 증가입니다. 이러한 암 진단 건수의 증가에 따라, 종양에 대한 신체의 면역 반응을 강화하는 효과로 알려진 더발루맙을 포함한 첨단 면역요법에 대한 수요가 높아지고 있습니다. 또한, 더발루맙의 적응증 및 용도 확대에 초점을 맞춘 지속적인 연구와 임상시험이 이 약물의 시장 내 입지를 강화할 것으로 기대됩니다. 맞춤형 의료에 대한 인식의 확산 또한 표적 치료에 대한 수요를 더욱 부추기고 있으며, 더발루맙은 암 치료 프로토콜에서 필수적인 요소로서의 입지를 확립해 가고 있습니다.
세계 더발루맙 시장의 시장 억제요인
세계 더발루맙 시장의 주요 시장 억제요인 중 하나는 치료비 급등과 의료 서비스 접근성 제한입니다. 더발루맙을 포함한 면역요법제의 높은 가격은 특히 개발도상국 지역에서 환자와 의료 시스템에 경제적 부담이 되어 이용을 제한할 가능성이 있습니다. 또한, 새로운 치료법에 대한 복잡한 규제 절차와 엄격한 승인 요건으로 인해 시장 진입이 지연되고, 더발루맙의 접근성이 제한될 우려가 있습니다. 이러한 요인에 더해 대체 요법의 존재까지 겹치면서 광범위한 보급을 실현하는 데 어려움이 발생하고, 결과적으로 시장의 성장 가능성을 저해하게 됩니다. 이러한 경제적 부담은 의료 서비스 제공자에게 압박을 가하여 치료 접근성 불평등으로 이어질 가능성이 있습니다.
세계 더발루맙 시장 동향
세계 더발루맙 시장에서는 병용요법의 채택 확대가 두드러진 추세로 나타나고 있습니다. 종양 전문의들은 항종양 효과를 높이고 환자의 예후를 개선하기 위해 더발루맙을 다른 체크포인트 억제제, 표적 치료제 및 화학요법과 병용하는 사례가 증가하고 있습니다. 학계와 산업계를 아우르는 임상 파트너십에 힘입은 이러한 협력적 접근 방식은 유망한 시너지 효과를 보여주고 있으며, 의료 제공자들이 다각적인 치료 프로토콜을 채택하도록 촉진하고 있습니다. 그 결과, 더발루맙의 임상적 적용 범위는 초기 적응증의 범위를 넘어 확대되고 있으며, 다양한 종양 치료 현장에서의 시장 침투를 촉진하는 동시에 환자 집단을 위한 맞춤형 의료 전략의 발전과 발맞추고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 더발루맙 시장 규모 : 적응증별
세계의 더발루맙 시장 규모 : 요법법별
세계의 더발루맙 시장 규모 : 유통 채널별
세계의 더발루맙 시장 규모 : 최종사용자별
세계의 더발루맙 시장 규모 : 제품 유형별
세계의 더발루맙 시장 규모 : 투여 경로별
세계의 더발루맙 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.08.05Global Durvalumab Market size was valued at USD 1.5 Billion in 2024 and is poised to grow from USD 1.64 Billion in 2025 to USD 3.29 Billion by 2033, growing at a CAGR of 9.1% during the forecast period (2026-2033).
Durvalumab, a human IgG1 monoclonal antibody targeting PD-L1, is significantly shaping the immuno-oncology market. Its initial approval for unresectable stage III non-small cell lung cancer (NSCLC), alongside subsequent indications for small-cell lung cancer and urothelial carcinoma, has led to increased physician adoption due to demonstrated superior survival rates compared to standard therapies. AstraZeneca's collaboration with Genentech has enhanced market access across regions, establishing a robust ecosystem involving manufacturers, payers, and oncology centers. Key growth drivers include an expanding indication portfolio that leverages checkpoint blockade mechanisms, alongside ongoing clinical studies in various cancers. Furthermore, AI-driven biomarker discovery is advancing personalized treatment regimens, optimizing patient selection and accelerating clinical uptake, thereby reinforcing Durvalumab's position in the market and encouraging investment.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Durvalumab market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Durvalumab Market Segments Analysis
Global durvalumab market is segmented by indication, therapy type, distribution channel, end user, product type, route of administration and region. Based on indication, the market is segmented into Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Biliary Tract Cancer, Hepatocellular Carcinoma and Others. Based on therapy type, the market is segmented into Monotherapy, Combination with Chemotherapy, Combination with Immunotherapy and Others. Based on distribution channel, the market is segmented into Hospital Pharmacies, Specialty Pharmacies, Oncology Pharmacies and Others. Based on end user, the market is segmented into Hospitals, Cancer Centers, Specialty Clinics and Others. Based on product type, the market is segmented into Branded, Biosimilar and Others. Based on route of administration, the market is segmented into Intravenous Infusion, Hospital Administration, Ambulatory Infusion Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Durvalumab Market
A key market driver for the global durvalumab market is the increasing prevalence of various cancer types, particularly non-small cell lung cancer (NSCLC) and other solid tumors. This uptick in cancer diagnoses is prompting a growing demand for advanced immunotherapy options, including durvalumab, which is known for its efficacy in enhancing the body's immune response against tumors. Additionally, ongoing research and clinical trials focused on expanding the indications and applications of durvalumab are expected to bolster its market presence. The rising awareness of personalized medicine further fuels the need for targeted therapies, positioning durvalumab as a vital component in oncology treatment protocols.
Restraints in the Global Durvalumab Market
One significant market restraint for the global Durvalumab market is the rising cost of treatment and limited access to healthcare. The high price of immunotherapy drugs, including Durvalumab, can restrict affordability for patients and healthcare systems, particularly in developing regions. Additionally, the complex regulatory processes and stringent approval requirements for new treatments may delay market entry and limit the availability of Durvalumab. These factors, combined with the presence of alternative therapies, create challenges in achieving widespread adoption, thus hindering the market's growth potential. This economic burden places pressure on healthcare providers and can lead to inequities in treatment accessibility.
Market Trends of the Global Durvalumab Market
The Global Durvalumab market is witnessing a significant trend characterized by the expanding adoption of combination therapy. Oncologists are increasingly integrating durvalumab with other checkpoint inhibitors, targeted therapies, and chemotherapy to enhance anti-tumor efficacy and improve patient outcomes. This collaborative approach, bolstered by clinical partnerships across academic and commercial sectors, demonstrates promising synergistic effects that are compelling healthcare providers to adopt multimodal treatment protocols. As a result, durvalumab's clinical applications are expanding beyond initial indications, driving its market penetration across various oncology settings and aligning with the advancing landscape of personalized medicine strategies for patient populations.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Durvalumab Market Size by Indication & CAGR (2026-2033)
- Market Overview
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
- Biliary Tract Cancer
- Hepatocellular Carcinoma
- Others
Global Durvalumab Market Size by Therapy Type & CAGR (2026-2033)
- Market Overview
- Monotherapy
- Combination with Chemotherapy
- Combination with Immunotherapy
- Others
Global Durvalumab Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Specialty Pharmacies
- Oncology Pharmacies
- Others
Global Durvalumab Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Cancer Centers
- Specialty Clinics
- Others
Global Durvalumab Market Size by Product Type & CAGR (2026-2033)
- Market Overview
- Branded
- Biosimilar
- Others
Global Durvalumab Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Intravenous Infusion
- Hospital Administration
- Ambulatory Infusion Centers
- Others
Global Durvalumab Market Size & CAGR (2026-2033)
- North America (Indication, Therapy Type, Distribution Channel, End User, Product Type, Route of Administration)
- US
- Canada
- Europe (Indication, Therapy Type, Distribution Channel, End User, Product Type, Route of Administration)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Indication, Therapy Type, Distribution Channel, End User, Product Type, Route of Administration)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Indication, Therapy Type, Distribution Channel, End User, Product Type, Route of Administration)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Indication, Therapy Type, Distribution Channel, End User, Product Type, Route of Administration)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BeiGene, Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Regeneron Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Genmab A/S
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Incyte Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Exelixis, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Arcus Biosciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Coherus BioSciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cullinan Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- MacroGenics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Immutep Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Compugen Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
